{"name":"NeuroDerm Ltd.","slug":"neuroderm-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Levodopa and carbidopa","genericName":"Levodopa and carbidopa","slug":"levodopa-and-carbidopa","indication":"Parkinson's disease","status":"marketed"},{"name":"ND0612","genericName":"ND0612","slug":"nd0612","indication":"Parkinson's disease with motor fluctuations in patients not adequately controlled by oral levodopa therapy","status":"phase_3"},{"name":"Oral IR-LD/CD","genericName":"Oral IR-LD/CD","slug":"oral-ir-ld-cd","indication":"Parkinson's disease motor fluctuations and wearing-off phenomena","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo for Oral IR-LD/CD","genericName":"Placebo for Oral IR-LD/CD","slug":"placebo-for-oral-ir-ld-cd","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Levodopa and carbidopa","genericName":"Levodopa and carbidopa","slug":"levodopa-and-carbidopa","phase":"marketed","mechanism":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.","indications":["Parkinson's disease","Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication"],"catalyst":""},{"name":"ND0612","genericName":"ND0612","slug":"nd0612","phase":"phase_3","mechanism":"ND0612 is a subcutaneous infusion formulation of levodopa/carbidopa that continuously delivers dopamine precursor to the brain to treat motor symptoms of Parkinson's disease.","indications":["Parkinson's disease with motor fluctuations in patients not adequately controlled by oral levodopa therapy"],"catalyst":""},{"name":"Oral IR-LD/CD","genericName":"Oral IR-LD/CD","slug":"oral-ir-ld-cd","phase":"phase_3","mechanism":"Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease.","indications":["Parkinson's disease motor fluctuations and wearing-off phenomena"],"catalyst":""},{"name":"Placebo for Oral IR-LD/CD","genericName":"Placebo for Oral IR-LD/CD","slug":"placebo-for-oral-ir-ld-cd","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9STnhGQXBEMExzc21pQ0FsWWVYX0x4clFKNHpqdk1Dem5VUlhEaU15Z3lwM2NoVU1rcWtCdzI0Q1hnbmNBd09MNTRvTDY2NmtlVFNEdzR4eXU?oc=5","date":"2026-03-18","type":"pipeline","source":"White & Case LLP","summary":"Jessica Chen - White & Case LLP","headline":"Jessica Chen - White & Case LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQREg4Z0FndjVsUFZOcjVTTTRyMHlCNlZ3NEhYZGs1SWdDRUVfcmpqTHRWN3RzNkg4UXhTOFM4UHE4aFVGV2Jfekx5R3M2NlRJZ0YxRVkwMGIxQ3VNTDNwT3ZMWFFYVjdRbEF0aF85b1JJQTE2SVhnbFRzM01kLWJCUHlyaFlSVHUzUUk0d21xVUotNUoxRlllZnd3SlhCZHF0UGItNUUwRklzWVJ1cmx4UlBvNF9mdDFGUXhZWlpFd1VKQnNISFVMT2VYOU8?oc=5","date":"2025-06-18","type":"pipeline","source":"Healio","summary":"A ‘wish come true’: Experts formally define on-treatment remission for plaque psoriasis - Healio","headline":"A ‘wish come true’: Experts formally define on-treatment remission for plaque psoriasis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPcEZ3akphekFNenRhNHQ4LVJmWGVoaHRmRUlBYUVwb0VRSFBlQ2REa1JobGhaRGZYNmhKdDBueEdVUVQxTkhrSnRpNGtNbDdoVk1jTHJJSnFlVkZ6T2l3RGtsanpuVm5XWFNOQ250LWNDcGRPcmlZMWd5UW1WUHo5dzhJTnhBZnEtUHBaUEtJaXA2LWstc3ZZWUQ4LUtSRUxYQ01fN0xR?oc=5","date":"2024-12-10","type":"pipeline","source":"BioSpace","summary":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace","headline":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNVzI5NXVCS2lwSk5KVDdDTkNrTk9kNG5hMThmZW9KQloxTWJfU0tYRVRteUMxLVVOdnN3T3RmdVZJNU9SbWprVG5rRURsVVFld1A2b082cmp6eEtPNG1oSDlkMFZhMXdja2ZoUWNiWXlkWDJrb2JkMm45NmM4TnJ1b2pjQ1o?oc=5","date":"2024-12-09","type":"pipeline","source":"PharmTech.com","summary":"European Biotechs Unlocking Parkinson’s Disease - PharmTech.com","headline":"European Biotechs Unlocking Parkinson’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQT2NpOUlCSWZJMVB3Z1VEdzBGWTRndW0xX1cyWTgyVU8zYWdXM290clNlSVl5ZnNtTGxDakc2MWxudXNTRWEwVkc2bG5EWGNwcFlFNjJRN3hvaEJhTTZKMUdrZ3Z3cUJQRlRjM3dKTUZrcGdvdkdqSll0QW03SjhyX3RYSV94dzVvN3JfS0g0VEhKRllGaXBqZDQ2LXZuWmdWMkxSdUx6NXBfbi1lcmJ3UXRWTVlSQXJ1OUVjT2tYN0FkT20teU1uaGY0aw?oc=5","date":"2023-09-20","type":"patent","source":"BioWorld News","summary":"Patent update: Neuroderm improves the design for its wearable anti-Parkinson’s infusion pump - BioWorld News","headline":"Patent update: Neuroderm improves the design for its wearable anti-Parkinson’s infusion pump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPd3o5S1B4UHExYm1XTHpFaE1La1lzUkxvUXZrQjc0THoyLTlPR3E2YXM4bGxiM003aDJzQ0ZYa2lRcjdnSUg3LVk4MWZXZGNNMUhQd3B5T1RhZHlCWDN4ZjNzemxxQ1V6OHdSYjFZaS1wdENQX1pfMXh1TUlLOGRzaG1RcGcwM1gxY3pQTTZOdlVYbDFPQ2hRZUlBXzNhRzVfNlVwMFVPNXZpTFpzUFo5eDNJbVNKQTF4Nmo5TjF3U3JLVl8zLUNyMFdDbkpaOFBDdVV4bnFITFlnYUdnamdBay1ILV9ONkcyVVhQMVBlUlFNSEphNHFFa3dFY2hyVU16RXFsZE9SN3NiM0hDU3VlREF4dnRUU2x6OUtlbnBHc2Fna1lSMmt3OEV2LWZpRWpkcUZOVk1qM1l3cUU?oc=5","date":"2023-01-09","type":"trial","source":"PR Newswire","summary":"NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations - PR Newswire","headline":"NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE5PS0RJektuWWJwZmt3SEFCeHdhcWh4bXBxUF82TklZYTZfaUNtRVJvUldwcXVWTGxHZVUtV01fcUtKbXd2VVRHZENSOEdYakVBMGRreEpoTkNHQVhfR0NoQ0hfdnNabnNTaW9ZVzctajNpMHFscWJF?oc=5","date":"2017-10-19","type":"deal","source":"CTech","summary":"Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm - CTech","headline":"Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPTkJwbnQ5ZmxJcGJwVnVUU1pFOHZCdWVzR0JlUnFubGJKVnV1QXdlN284RnpZVExyM1h1elFvTEgwbVRXMFJEdC1uSGd6SUJ2WXBCX2tOQnFYWVBJaXNPQXhiY2VDcmpjZEc0RHh3NHZMcFN3MVEyU3VYa3NJTnhHMXE2YzVyZEo1blR1bUFaTW93d0JZTUlJbkVHZzJFaEpBck5qeUd2a0MyNm91Y1lXTzc5YUVETEtCXzQ2VDVqZzYwNDFHa0stS0wtS0xYV2Y1ZGRYVFA3bm9WSlM4SDM4RE84eGk5eTJUQ2N2dEltNmNfUW9aODZJWXFwV2JqTmp2d2RmczV2QmxJNndMWGR2TXg5Y242TTJnLTZn?oc=5","date":"2017-07-24","type":"deal","source":"GlobeNewswire","summary":"NeuroDerm Enters Definitive Agreement to be Acquired by - GlobeNewswire","headline":"NeuroDerm Enters Definitive Agreement to be Acquired by","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOaEcxRXh5eXN5a3F1Q3ZOcHVtZkpmcEktZ00wVkJuOWk2N2NET3ltaEdEakp6eG1oRnpCZldSaTl1YWhSVDZJQVBQWXZNUXBKSEpYcTF5MDZ2cWtXMkJjU2U4Slgxem1acERLWnA4VVNLT1NzZXYxT19OZUVBWHM1NENIZDR3eFZmUzByelFSZnU1Z0k?oc=5","date":"2017-07-24","type":"deal","source":"BioPharma Dive","summary":"Mitsubishi Tanabe to acquire NeuroDerm for $1.1B - BioPharma Dive","headline":"Mitsubishi Tanabe to acquire NeuroDerm for $1.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBvRFM1bTl4enUyWmtvN0x1d1JJVzdhd1BISlNac1BqXzJBT2ttSHBkWnBCb0ZBRkxHYmpfMnlXeDBQblJiSk9CdEx6Z21Jamt2VWpxRHFUcHFXX3F6cldtTHlUSzRUWVZ5ZUN3eFFJZXdha1U2?oc=5","date":"2017-07-24","type":"deal","source":"Fortune","summary":"Mitsubishi Tanabe Pharma to Buy Israel's Neuroderm for $1.1 Billion - Fortune","headline":"Mitsubishi Tanabe Pharma to Buy Israel's Neuroderm for $1.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQUUtldGVyR25JUmVYOGZTOWIyR1ZpOXFsbksxR2RzRDJoTWpQNEVEeGNmVEZWek1ZblJzbGRmbkRMUnRKRWpwaWpYemtlZUc3ZUtxbThlODc2SXdUUnhESnZPNWxtVm9KYnc1VjJpNjNEWTlYZzBJRzU2STl0ZTlkOHpXWnlrVHFpUmR1UmNnSQ?oc=5","date":"2017-07-24","type":"pipeline","source":"Globes - Israel Business News","summary":"Israeli pharma co NeuroDerm sold for $1.1b - Globes - Israel Business News","headline":"Israeli pharma co NeuroDerm sold for $1.1b - Globes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQRFBQVnVDRmZxOU1vY1FnNG1VNmZPX2xXT2h1SzBQRlBPTUhsOU5ERTB0Z3g3Z29COF9IT29uMVRENVZKRFJqcVZOUS1YazdXWU0tUHJUaUdKNHh4ZUMzV1pVUGxQWmFINkpqUzljMnl3TkRfdEcwNVNPcmgwQW9wRm1FR2JGVDNJaVlMMnNKVEgzdXJMZDRMM0lFTzF0alFsOE9Zd1JtRVMwcUczamhFeGFDNXAtdU9JU3J6QXA5SEY0M0p3cHlPYzR0UzUxOUNWc1hqTGJtbkxQWFFNOUJhM2RqQ2Zoa2lCRnI1ZUVVZVhzaDFjZGhlRTEwazJnZw?oc=5","date":"2017-07-24","type":"pipeline","source":"Haaretz","summary":"Israeli Medi Tech Firm NeuroDerm Sold to Japanese Firm for Whopping $1.1 Billion - Haaretz","headline":"Israeli Medi Tech Firm NeuroDerm Sold to Japanese Firm for Whopping $1.1 Billion","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":3},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}